Smart Money Is Rotating Into Healthcare AI: What ARK Invest’s $87M Big Tech Selloff Signals for Precision Medicine
When one of the most closely watched innovation investors on the planet dumps $87 million in Nvidia and Meta over two days and immediately redirects that capital into healthcare AI and genomics companies, it sends a signal that the broader market would be wise to pay attention to.
Presented By Our Partners
That is exactly what happened last week. Cathie Wood’s ARK Invest executed a sweeping portfolio rotation, liquidating more than 213,000 shares of Nvidia across three ETFs (worth over $37 million), 76,622 shares of Meta Platforms (worth approximately $45.6 million), and trimming positions in AMD, Taiwan Semiconductor, and Broadcom. The semiconductor and consumer tech selloff totaled roughly $84 million in a single trading session on March 26 alone.
Where did that capital go? Straight into the companies building the future of precision medicine.
Tempus AI: The Precision Oncology Platform That Merck Just Bet On
ARK purchased approximately 146,000 shares of Tempus AI across its ARKK and ARKG funds, valued at around $7 million, and continued adding to its position across multiple trading days. Tempus AI (NASDAQ: TEM) maintains one of the world’s largest libraries of multimodal clinical and molecular data, and its Lens Platform uses AI to help physicians deliver personalized treatment decisions at the point of care.
The institutional validation is stacking up. In March 2026, Tempus announced an expanded, multi-year strategic collaboration with Merck to accelerate AI-driven precision medicine biomarker discovery across oncology. Northwestern Medicine selected Tempus to expand genomic testing access for cancer patients earlier this year. And the precision medicine software market is projected to grow from $2.45 billion in 2025 to $4.92 billion by 2030.
Tempus reported Q4 2025 revenue of $367.2 million, an 83% year-over-year increase, with full-year revenue hitting $1.27 billion. The company’s 2026 guidance targets approximately $1.59 billion in revenue with positive adjusted EBITDA of $65 million. This is a company that has crossed the threshold from promising healthtech startup to scaled precision medicine infrastructure.
Featured Partner
Invest in the Infrastructure Behind Modern Medicine
As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.
Learn More →
GeneDx Holdings: Genomic Diagnosis at Scale
ARK bought 20,674 shares of GeneDx Holdings (NASDAQ: WGS) on Monday, March 30. GeneDx is the global leader in rare disease genomic diagnosis, having sequenced nearly one million exomes and genomes across more than 25 years. Its GeneDx Infinity dataset is the world’s largest rare disease genomic dataset, and the company’s AI-powered Multiscore tool is accelerating diagnostic efficiency.
GeneDx’s CEO Katherine Stueland was named to the 2026 TIME100 Health list. The American Academy of Pediatrics now recommends exome and genome sequencing as first-tier tests for children with developmental delay. GeneDx has expanded into prenatal diagnostics with GenomeDx Prenatal and launched ultraRapid genome sequencing that delivers results to NICU and PICU patients in as little as 48 hours.
The financial trajectory mirrors the clinical impact. GeneDx reported 2025 revenues of $427 million with 54% exome and genome revenue growth, and issued 2026 guidance of $540 to $555 million in revenue with 33 to 35% continued growth. Adjusted gross margins sit at 71%.
CRISPR Therapeutics and the Gene Editing Frontier
CRISPR Therapeutics (NASDAQ: CRSP) remains one of ARK’s largest holdings, representing the therapeutic application of genomic science. While Tempus and GeneDx are building the diagnostic and data infrastructure layers of precision medicine, CRISPR is working at the treatment layer, developing gene-editing therapies that can fundamentally alter disease at the molecular level.
Wood’s thesis is clear: diagnostics, data platforms, and therapeutics form a convergent ecosystem. The companies that own the data, the algorithms, and the editing tools will define the next era of medicine.
The Broader Pattern: 10x Genomics and Arcturus Therapeutics
ARK’s healthcare rotation extended beyond the headline names. The firm added over 121,000 shares of 10x Genomics (worth approximately $2.5 million), a spatial biology and single-cell genomics company whose tools are foundational to understanding disease at the cellular level. Arcturus Therapeutics, an mRNA medicines company, saw over 53,000 shares added to ARK’s position.
Every buy on the list last week ties back to a single thesis: the most transformative applications of artificial intelligence are not in consumer social media or general-purpose cloud computing. They are in healthcare.
What This Means for the Future of Medicine
When institutional capital of this magnitude shifts from big tech into healthcare AI and genomics, it reflects a maturation in how the market understands artificial intelligence. The initial wave of AI investment was about infrastructure: chips, cloud, and compute. The next wave is about application, and the highest-value application domain is human health.
Precision medicine is no longer a theoretical promise. It is a scaled, revenue-generating sector with billion-dollar companies, enterprise partnerships with major pharmaceutical firms, and clinical integrations at leading health systems. The convergence of genomic data, AI-driven diagnostics, and targeted therapeutics is creating an ecosystem that will reshape how disease is detected, understood, and treated for every patient.
The smart money has spoken. Healthcare AI is not a subcategory of the technology sector. It is the main event.
Similar Posts
Your Immune System Is Aging Because Your Mitochondria Are Failing: How Mitophagy Activation Is Reversing Immune Decline in Clinical Trials
A landmark clinical trial published in Nature Aging shows that urolithin A, a natural mitophagy activator, rejuvenated immune cell populations in middle-aged adults in just 28 days. The MitoImmune trial expanded naive CD8+ T cells, boosted fatty acid oxidation capacity by nearly 15 percentage points, and shifted immune transcription toward a younger profile. Here is what the science of mitophagy means for immune aging and your health.
MIR Smart One Spirometer Review: The Most Portable FDA Cleared Spirometer for Telehealth and Daily Lung Monitoring
Pocket sized, Bluetooth connected, and FDA cleared, the MIR Smart One puts clinical spirometry in a form factor smaller than a smartphone. Presented By Our Partners The history of spirometry spans over 150 years, from the cumbersome water displacement spirometers of the 19th century to the desktop turbine devices that occupy every pulmonologist’s office today….
The Daily Rounds: Longevity & Health Care Brief | March 31, 2026
🧠- Heidelberg scientists have identified a protein pairing that acts as a molecular "death switch" in Alzheimer's disease, and a new compound can break it apart, protecting neurons even as it reduces amyloid.
🧬 - The first-ever human trial of partial epigenetic reprogramming is now enrolling, with Life Biosciences testing ER-100 in patients with retinal degeneration in a trial that could redefine what it means to treat aging at the cellular level.
💊 - GLP-1 receptor agonists do not cause disproportionate muscle loss, and new data shows they actually increase mitochondrial proteins in skeletal muscle, suggesting metabolic benefits that go well beyond weight reduction.
🦠- Gut bacteria are actively injecting proteins into human intestinal cells via molecular syringes, and this mechanism appears more prevalent in people with Crohn's disease, pointing to a new pathway for understanding and treating chronic gut inflammation.
⌚ - ARPA-H's new Delphi program is funding wearable biosensors that can continuously track cytokines and hormones in real time, a potential leap from tracking symptoms to detecting the earliest biological signals of disease and aging.
Biobeat BB-613: FDA Cleared Cuffless Blood Pressure Monitoring for Clinical Use
The first FDA cleared cuffless blood pressure monitor designed for clinical and remote patient monitoring, using a chest worn patch to continuously track blood pressure, heart rate, respiratory rate, and oxygen saturation. Presented By Our Partners For over a century, blood pressure measurement has required compression of an artery, typically with an inflatable cuff at…
The Stanford Fermented Foods Study: What It Means for Gut Health, Inflammation, and Longevity
A landmark 2021 Stanford study found that a diet rich in fermented foods increased gut microbiome diversity and lowered 19 inflammatory proteins, while a high fiber diet did not. Here is what the science shows, how it connects to the four fundamentals of nutrition, breath, sleep, and movement, and what you can do starting with your next meal.
Nurvv Run Smart Insoles: Pressure-Based Gait Analysis and Injury Prevention
Every running injury begins with a biomechanical pattern the runner cannot feel. The question is whether wearable technology can detect that pattern before the injury announces itself. Presented By Our Partners Running-related injuries affect an estimated 37% to 56% of recreational runners annually, with the majority classified as overuse injuries driven by repetitive biomechanical stress….
